"We currently are utilizing sophisticated, controlled-release tablet technology to enable targeted delivery of oral Brilacidin in the colon, with in-human testing anticipated to start as soon as year-end."

Does this actually mean a B-P2 possibly by end of year or does it mean BDD will be testing their technology on humans this year and not B for IBD itself?

If it's B-P2 then where's that money coming from. Sure not from B-UP license.
Leo would need another deal to pay for that.